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ABSTRACT 
Objective 
CD8
+
T cells are abundant in rheumatoid arthritis (RA). However, their role in the disease 
pathogenesis is poorly defined. Here we investigated the relationship between disease 
activity and CD8
+
T cell phenotypes, production of cytokines and cytotoxic molecules in RA 
peripheral blood (PB) and synovial fluid (SF). 
Methods 
CD8
+
T cell phenotypes were determined in 96 patients with RA (44 in remission, 34 with 
active disease) and in 64 gender and age-matched healthy controls (HC). Ten paired PB and 
SF samples from patients with active RA were analyzed. The expression of surface markers, 
cytokines and proteolytic enzymes in CD8+T cells was evaluated using flow-cytometry. 
Results 
The PB CD8
+
T cells from RA patients with active disease exhibited an effector CD27
-
CD62L
-
 
(p=0.005) phenotype with elevated proinflammatory cytokine expression (TNF-α, IFN-γ, IL-6, 
IL-17A) when compared to HC. The phenotype observed in patients with active disease 
persisted in remission, with a significant increase in the frequency of CD69 (p<0.001) and 
was associated with lower cytokine production. CD8
+
T cells from SF expressed more robust 
effector memory (CD27
+
CD62L
-
) and activated (CD69
+
) profiles compared with paired blood-
derived subsets. Cytokine-production (IL-6, IL-17A, and IFN-γ) by CD8
+
T cells from PB and SF 
was positively correlated within individual donors. The production of cytokines (TNF-α, IFN-
γ, IL-17A) by CD8
+
T cells in the PB from RA patients positively correlated with DAS28. 
Conclusion 
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Herein we characterize the activation status and proinflammatory potential of CD8
+
T cells 
subsets in RA patients. This activation status strongly suggests a local and systemic effector 
cytotoxic role in the disease.   
 
INTRODUCTION 
Genome-wide association studies and long standing phenotypic and relevant murine model 
data strongly implicate T cells in the pathogenesis of rheumatoid arthritis (RA). CD8
+
T cells 
comprise approximately 40% of all T cells infiltrating the rheumatoid synovial compartment 
(1), and they are detected in the pre-clinical stages of disease development(2). CD8
+
T cells 
can be subdivided into different functional subsets that include a short-lived effector subset 
(with high migratory capacity and intense production of pro-inflammatory cytokines and 
cytotoxic molecules); an effector-memory subset (which accumulates in the peripheral 
organs, is apoptosis-resistant and becomes effector upon reencounter with antigen), a 
central memory subset (which offers rapid proliferation and cytokine production but little 
cytotoxicity upon reencounter with cognate antigen), and a suppressor subset (IL-10-
producing cells which down-modulate the inflammatory response) (3-5). 
One prior study found that peripheral blood (PB) central memory CD8
+
T cells were more 
frequent in RA patients when compared to healthy controls (HC) whereas the opposite 
profile was seen with effector memory CD8
+
T cells. (6). Recently, the frequency of effector 
memory but not central memory CD8
+
T cells was reported to be elevated in the PB and 
synovial fluid (SF) of RA patients when compared to PB samples from HC (7). An 
accumulation of autoreactive, clonally-related memory CD8
+
T cells was found in RA SF (8-11) 
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and their frequency correlated with serum rheumatoid factor (RF) levels (12). RA patients 
with DAS28>3.2 appear to have a slight increase in the frequency of circulating IL-17A-
producing CD8
+
T cells (13). CD8
+
T cells are crucial in maintaining synovial ectopic germinal 
centers, which are associated in turn with more aggressive disease (14-16). However, some 
studies indicate that a suppressor subset of CD8
+
T cells associates with disease amelioration 
(17, 18). Key outstanding questions remain including the identity of an overarching 
phenotype and the production of cytokines and cytotoxic molecules by CD8
+
T cells in 
peripheral blood and the synovial compartment and their relationship with RA disease 
activity. As SF is becoming harder to obtain, it must be established whether studies in blood 
samples provide a reliable representation of the biological events taking place at the 
inflammatory site, reflected by the SF.  Herein we address these critical issues. 
 
PATIENTS AND METHODS 
Patients 
96 RA patients from Rheumatology Department of Centro Hospitalar Universitário de 
Coimbra were enrolled for this study (Table 1). RA disease activity was assessed at the time 
of blood collection through tender and swollen joint counts, Erythrocyte Sedimentation Rate 
and C-reactive protein) levels. Disease activity groups were defined according to the DAS28-
CRP (3 variables) score: <2.6= remission; ≥2.6 <3.2= low; >3.2= moderate to highly active 
disease(19). SF was collected from patients with active disease whenever possible (n=10). 
The use of different medications was very similar in the three disease-activity groups, with 
the exception of anti-TNF agents, used by five patients, all with active disease. On average, 
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patients were receiving a combination of 3 different medications for RA, this number being 
similar in the different disease activity groups. A total of 64 gender and age-matched healthy 
individuals (HC) were recruited among family members of patients in the same Department. 
Exclusion criteria: known or suspected ongoing infections, or, for HC, any history of 
autoimmune disease or immunosupressive therapy. 
The study was approved by the institutional ethics committee and performed according to 
the Helsinki declaration on studies with human subjects. All subjects signed an informed 
written consent prior to any study procedure. Table I summarizes the demographic, clinical 
and therapeutic data of all subjects. 
Flow cytometric analysis 
After red blood cell lysis using a hypotonic solution, unstimulated PB mononuclear cells were 
stained for cell surface markers using fluorochrome-conjugated mouse anti-human 
monoclonal antibodies against: CD8, CD25, CD27, CD4, CCR7, CD62L, CD69, CD3 and CXCR4 
(all from Biolegend). For intracellular cytokine quantitation, after staining for the cell surface 
antigens, samples were formalin-fixed and permeabilized using a saponin-based buffer prior 
to incubation with fluorochrome-conjugated mouse anti-human monoclonal antibodies 
against: IFN-γ, Granzyme B, IL-17A, TNF-α, IL-6, IL-10 (all from Biolegend) and Perforin 
(Immunotools). Irrelevant, directly conjugated, murine IgG1 or IgG2 (Biolegend) were used 
to ascertain background staining. All samples were analyzed on a FACScalibur cytometer 
(BD), with 50000 events collected within the lymphocyte gate. After calibration with CST 
beads single-fluorochrome stained cells were used for instrument compensation and PMT-
setup. Resulting data were quantified using FlowJo Software (Treestar). Analysis of CD8
+
T 
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cell subsets (Supplemental table I summarizes the markers profile for each subset) was 
performed on total CD8
+
T cells in the lymphocyte gate.  
Statistical analysis 
SPSS v.20 (IBM) was used to analyze the results. We elected to compare cells obtained from 
people with active RA (DAS28>3.2), vs cells from RA patients in remission (DAS28<2.6) vs 
cells obtained from age and gender-matched HC. Differences between independent samples 
were assessed through one-way ANOVA followed by LSD post-hoc test. Paired PB and SF 
samples were compared through the Wilcoxon rank sum test. Correlation between PB and 
SF was analyzed using Spearman correlation coefficient. Correlation between DAS28 and PB 
CD8
+
T cells was analyzed using the Pearson correlation including all RA patients. PB CD8
+
T 
cells were also correlated with MTX and GC´s doses through Pearson Correlation. Correlation 
coefficients were considered weak for R above 0.1, moderate for R values above 0.3, strong 
above 0.5 and very strong above 0.75. 
In order to explore whether the influence of therapy upon the changes in biological 
parameters significantly correlated with DAS in univariate analysis, we performed a 
multivariate linear regression analysis of these measures, including the doses of medications 
(methotrexate, antimalarials, glucocorticoids and sulfasalazine) and DAS28 as covariates. 
Statistical significance was considered for p<0.05 in all analyses. 
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RESULTS 
Altered status of peripheral blood CD8
+
T cell subsets in RA patients 
The relative frequency of circulating CD8
+
T cells within the total lymphocyte population was 
similar in all groups (Fig 1A). The absolute number of circulating CD8
+
T cells was similar in RA 
patients with active disease and in controls but was significantly lower (p<0.05) in patients in 
remission (HC: 394.2±1.6cells/µl; Active RA: 400.0±3.7cells/µl; Remission RA: 
351.7±1.6cells/µl). This apparently arises from generalized lymphopenia in RA patients in 
remission (HC: 2478.3±156.4 cells/µl; Active: 2185.7±266.8 cells/µl; Remission: 
1825.0±159.6 cells/µl) and suggests that the latter status is not commensurate with normal 
immunologic homeostasis. 
The relative frequencies of CD27
+
CD62L
+
CCR7
+
 central memory CD8
+
T cells  was lower in 
active RA than in HC (Fig 1B). Remission was associated with accentuation of this difference 
(Fig 1B). The frequency of CD27
+
CD62L
-
 effector memory CD8
+
T cells was similar in all three 
groups (data not shown). The frequency of the short-term effector CD27
-
CD62L
-
CD8
+
T cell 
subset was significantly higher in the active disease group when compared to controls (Fig 
1B). This difference persisted in patients in remission. 
Both RA groups had lower relative frequencies of CD25
+
CD8
+
T cells compared with HC, 
although significant differences were observed only for those patients in remission (Fig 1C). 
The frequency of PB CD69
+
CD8
+
T cells in active disease was similar to that in HC. The 
remission group had significantly more circulating CD69
+
CD8
+
T cells than the active disease 
and the HC (Fig 1C). There was an accumulation of CD69-expressing CD8
+
T cells within the 
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total CD62L
-
 effector compartment of both patient groups – especially in the remission 
group - when compared to HC (Fig 1C). The frequency of PB CD8
+
T cells expressing CXCR4 
was significantly lower in both patient groups than in controls (Fig 1D). When focusing the 
analysis on the activated total effector CD8
+
T cell population, the significant reduction of the 
proportion of cells expressing CXCR4 was maintained in both patient groups when compared 
to HC (Fig 1D). 
 
Cytokine and cytolytic enzyme expression by CD8
+
T cells in RA 
Patients with active RA had a significantly higher percentage of unstimulated CD8
+
T cells 
expressing TNF-α, IL-17A, IL-10 and granzyme B than controls (Table II). Patients in remission 
exhibited a higher than normal percentage of IL-10
+
CD8
+
T cells, but not TNF-α, IL-17A or 
granzyme B expressing cells. The frequency of CD8
+
T cells producing other cytokines was 
similar across groups. Intracellular expression of cytokines, granzyme B and perforin in 
unstimulated PB CD8
+
T cells (Table II) was quantified by mean fluorescence intensity (MFI). 
CD8
+
T cells from active RA expressed significantly more granzyme B, IL-6, IL-17A, TNF-α and 
IL-10 than cells from control donors. CD8
+
T cells from remission RA patients expressed 
significantly less IL-6, IL-17A, TNF-α and IFN-γ than those obtained from active RA.  
 
Functional CD8
+
T cell subsets in paired blood and SF samples of RA patients 
Cell phenotypes in RA SF were compared with paired PB. The frequency of effector memory 
CD8
+
T cells was significantly higher in SF than in paired PB (Fig 2A). CD8
+
T cells expressing 
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CD25 and CD69 were significantly more frequent in the SF than in the PB (Fig 2B). Similarly, 
the frequency of CD69
+
CD62L
-
 activated effector CD8
+
T cells was significantly higher in SF. 
There was a significant accumulation of CXCR4
+
CD62L
-
 and CXCR4
+
CD69
+
 CD8
+
T cells in the 
SF (Fig 2C). The frequency of TNF-α-expressing and IL-6-expressing CD8
+
T cells was 
significantly higher in the RA SF than in PB. However, no significant differences were 
observed in the frequency of CD8
+
T cells expressing other cytokines or granzyme B (Table 
III). Finally, the intracellular production of all cytokines and granzyme B by SF CD8
+
T cells was 
similar to that in PB (Table III). 
 
Correlation of CD8
+
T cell subsets in the PB and SF 
The frequencies of total CD8
+
T cells in SF and PB had a strong positive correlation (Fig 3A). 
The percentages of total activated CD25
+
CD8
+
T cells and the CD25
+
CD62L
+
 memory subset in 
PB presented a strong positive correlation to the percentage of the same subsets in the SF 
(Fig 3A). Strong positive correlations were found between the intracellular production of 
granzyme B, IFN-γ, IL-6, IL-17A by CD8
+
T cells from PB and SF (Fig 3B). 
 
Correlation of PB CD8
+
T cell subsets with DAS28 and influence of therapies 
The frequency of total CD8
+
CD69
+
CXCR4
+
 and CD8
+
CXCR4
+
CD62L
-
 T cells in PB exhibited a 
weak negative correlation with DAS28 (Fig 3C). Weak positive correlations with DAS28 were 
found for the intracellular production of TNF-α and IL-17A, whereas intracellular IFN-γ 
presented a strong positive correlation (Fig 3D).  
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The correlations between the dose of medications (MTX, sulfasalazine, hydroxychloroquine 
and glucocorticoids) and CD8
+
T cell subpopulations, as well as intracellular proinflammatory 
mediator production, assessed through multivariate analysis as described, failed to show 
statistically significant impact of medications after consideration of DAS28 (supplemental 
table II). 
DISCUSSION 
Herein we report that PB CD8
+
T cells from active and remission RA present an activated 
phenotype with a marked pro-inflammatory profile. We show that the expression of pro-
inflammatory cytokines by circulating CD8
+
T cells is directly correlated with the DAS28 score. 
CD8
+
T cells from the SF of active RA exhibit an exacerbated effector and activated 
phenotype compared to those in paired PB. Finally, we observed that the production of 
cytokines by SF CD8
+
T cells is correlated with that in paired PB derived cells. 
Contrasting to a previous report (7), we did not find any differences in the frequency of total 
CD8
+
T cells in PB and SF of RA patients. We suggest that these contradictions arise from the 
fact that they compared SF data to blood data of the whole RA cohort regardless of disease 
activity, whereas we performed a paired analysis restricted to patients with active disease. 
The circulating CD8
+
T cell compartment of RA patients, regardless of disease activity, had a 
skewed distribution of central memory and short-term effector CD8
+
T cell subsets, with 
enrichment of the latter. Accumulation of effector memory CD8
+
T cells in the SF compared 
to the paired blood was equally present. RA patients accumulate effector CD8
+
T cells both in 
the blood and in the SF - and at the same time present a reduction in the central memory 
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CD8
+
T cell subset. These results partially mimic our previously reported observations in 
K/BxN mice (20).  
Our data confirm previous observations that CD8
+
T cells in RA frequently express the early 
activation marker CD69 (21-24). The increased frequency of effector CD8
+
T cells expressing 
CD69 in RA patients’ blood – independent of disease activity – and SF, suggests that these 
cells might be constantly stimulated by the presence of their cognate antigen(s). Also in the 
K/BxN model of arthritis, the expression of CD69 in CD8
+
T cells is increased in both the PB 
and articular tissue of arthritic mice (20). These data, together with previous studies, 
indicate that activated CD8
+
T cells are enriched in RA PB cells (25). Even though, the 
peripheral blood only represents a small fraction of the total T cell pool of an individual, we 
speculate that the accumulation of activated CD8
+
T cells in the PB during remission rather 
than active disease suggests that these cells remain in circulation and might be recruited into 
the joint when the disease increases its activity. The surge in CD8
+
T cells expressing CD69 as 
well as CD69
+
CXCR4
+
 in the SF of active RA patients when compared to parallel PB samples, 
also indicates that these cells are enriched in the joints during disease flares. This 
interpretation is supported by our finding of a weak negative correlation between the 
frequency of PB effector and activated CXCR4
+
CD8
+
T cells and the DAS28 score, since CXCR4 
is responsible for cytotoxic T cell-homing into inflammatory sites. Clearly, the correlations 
are too weak to establish this functional link but they mirror our previous results in the 
K/BxN mouse (20).  
We measured ex vivo cytokine, perforin and granzyme B production by PB and SF CD8
+
T cells 
without in vitro stimulation, in order to assess whether these cells actively contribute to the 
pro-inflammatory environment in RA and consequent joint destruction. Our data show that 
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regardless of the similar numbers of circulating effector CD8
+
T cells, remission and active 
disease are associated with distinct production of cytokines and cytotoxic molecules, and 
that the production of pro-inflammatory cytokines in PB was directly correlated with the 
DAS28 score. 
We show that the expression of granzyme B by CD8
+
T cells from PB and SF from active RA 
patients is higher than in PB from controls. The difference between remission and control is 
not significant. We confirm previous observations that granzyme B
+
CD8
+
T cells are 
commonly found in the synovium of RA patients (16, 26). Given that we excluded patients 
with known ongoing infections, we suggest that the increased production of granzyme B and 
perforin by CD8
+
T cells in active RA is stimulated by the presence of autologous antigens and 
the pro-inflammatory environment. It also shows that CD8
+
T cells are actively involved in 
maintaining the chronic inflammatory process and that after medication-induced remission 
granzyme B and perforin production by CD8
+
T cells returns to normal levels.  
The positive correlations obtained between the intracellular production of Granzyme B, IL-
17A, IL-6 and IFN-γ by CD8
+
T cells in the PB and those in the SF indicate that variations 
observed in the patients’ PB mirror those in the SF. Hence, we demonstrate, for the first 
time, that variations in the production of these cytokines on peripheral CD8
+
T cells provide a 
good representation of similar processes taking place at the joint level. This is an important 
finding, given that synovial fluid is now rarely available for research. Contrasting to previous 
suggestions derived from studies with unpaired PB and SF samples (27, 28) we did not 
observe an enrichment of IFN-γ
+
CD8
+
T cells in the SF of RA patients. 
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A higher expression of IL-6 and TNF-α by CD8
+
T cells from the PB was present in patients 
with active disease, highlighting the contribution of CD8
+
T cells to the generalized 
inflammatory processes underlying RA. We observed a tendency to an expanded IL-10
+
CD8
+
T 
cell pool in the SF when compared to the paired blood RA samples, which was accompanied 
by a tendency for more IL-10 production by these cells. These observations confirm previous 
reports (7, 27) and seem to represent a mechanism to control inflammation.  
Our results show that increased IFN-γ-production by PB CD8
+
T cells is directly correlated with 
DAS28. This directly implies these activated T cells in the autoimmune reaction. We have 
carefully scrutinized the potential relationship between medications and this observation, 
through multivariate analysis. No influence of any of the medications upon this parameter 
persisted significant after considering DAS28.  
Overall, our observations support the following model: active RA disease is characterized by 
a marked enhancement of CD8
+
T cells’ effector properties, and homing of those subsets into 
the joints (see supplemental figure). The expression of pro-inflammatory cytokines by CD8
+
T 
cells in the PB (and SF) is strongly correlated with disease activity, suggesting that these cells 
have a relevant contribution to the systemic inflammatory milieu. After therapy-induced 
remission, CD8
+
T cells recover some characteristics typical of healthy individuals, with 
significant reduction of cytokine production. However, some significant alterations, such as 
increased effector and activated phenotype, still persist and may be capable of maintaining 
the disease in a new biological equilibrium, with the potential to relapse. Through 
multivariate analysis we could not find a significant impact of any of the medications used, 
upon the frequency of CD8
+
T cell subpopulations and intracellular production of effector 
molecules, after considering DAS28. Despite this, we believe that the influence of 
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medication cannot be securely ruled-out by our data, given the limited sample size and the 
multiple combinations of therapies used. 
Our results suggest that CD8
+
T cells play a bigger role in RA than recognized in current 
paradigms of the disease pathogenesis and maintenance, according to which pathogenic T 
cells are HLA class II-restricted, i.e. CD4
+
. Further investigation is warranted to clarify their 
involvement in disease onset and course, joint destruction and response to therapy.  
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Table I– Clinical characteristics of RA patients and healthy donors.  
 
Therapy 
Controls Total RA Active Low Remission 
          
N (SF donors) 64 96 (10) 34 (10) 18 (0) 44 (0) 
Gender (F:M) 55:19 77:19 27:7 14:4 36:8 
Medication - N (Avg. Dose) 
     
MTX  - 82 (17.4 mg/wk) 27 (19.5 mg/wk) 15 (16.3 mg/wk) 39 (16.3 mg/wk) 
Hydroxychloroquine - 21 (366.7 mg/day) 9 (344.5 mg/day) 2 (400 mg/day) 10 (380 mg/day) 
Sulfasalazine - 20 (1800 mg/day) 6 (1916.7 mg/day) 3 (1833.3 mg/day) 11 1727.3 mg/day) 
Prednisolone - 55 (5.3 mg/day) 21 (6 mg/day) 10 (5.8 mg/day) 25 (4.4 mg/day) 
Leflunomide - 2 (15 mg/day) 1 (20 mg/day) 1 (10 mg/day) 0 
Azathioprine  - 1 (20 mg/day) 0 0 1 (20 mg/day) 
Folic Acid  - 56 (7,95 mg/wk) 18 (8.9 mg/wk) 8 (6.3 mg/wk) 29 (7.9 mg/wk) 
NSAIDs - 50 19 9 22 
TNF inhibitors - 5 5 0 0 
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Table II– Frequency of intracellular cytokines expression and their respective MFI in 
peripheral blood CD8
+
T cells from RA patients and healthy controls.  
 
Ctrl Active RA Remission  One way ANOVA
 
 
Mean ± SEM
a
 
(n=64) 
Mean ±  
SEM (n=34) 
Mean ± 
SEM (n=44) 
p (Active 
vs Ctrl) 
p (Rem. 
vs Ctrl) 
p (Active 
vs Rem) 
Intracellular cytokines (% from total CD8
+
T cells) 
IL-6 2.3 ± 0.5 1.6 ± 0.2 1.7 ± 0.2 NS
b
 NS NS
a 
TNF-α 1.2 ± 0.2 2.2 ± 0.4  1.8 ± 0.2 0.016 NS NS 
IFN-γ 2.2 ± 0.7 3.9 ± 1.2 2.4 ± 0.4 NS NS NS 
IL-17A 1.5 ± 0.2 3.6 ± 0.8 2.3 ± 0.5 0.004 NS NS 
IL-10 0.9 ± 0.1 1.5 ± 0.2 1.8 ± 0.5 0.051 0.007 NS 
GrzB
c
 14.8 ± 2.0 23.5 ± 3.7 16.2 ± 3.0 0.028 NS NS 
Perforin 2.6 ± 0.7 4.9 ± 2.1 2.0 ± 0.6 NS NS NS 
 
MFI
d
 (within the cytokine-positive CD8
+
T cells) 
IL-6 13.0 ± 1.2 22.5 ± 4.0 14.4 ± 1.2  0.003 NS 0.015 
TNF-α 11.9 ± 0.5 18.2 ± 2.1 13.4 ± 0.7 >0.001 NS 0.006 
IFN-γ 24.8 ± 1.6 26.1 ± 3.7  15.4 ± 1.2 NS 0.002 0.001 
IL-17A 17.8 ± 3.4 28.6 ± 2.9  18.5 ± 1.6 0.011 NS 0.022 
IL-10 11.1 ± 0.6 17.4 ± 1.4  19.5 ± 1.8 0.015 NS NS 
GrzB 29.7 ± 2.6 64.0 ± 15.3 45.7 ± 11.7 0.012 NS NS 
Perforin 12.5 ± 0.6 22.3 ± 6.5 15.6 ± 1.4 0.030 NS NS 
a) SEM: standard error of mean; b) NS: non-significant: c) GrzB: Granzyme B, d) MFI: 
mean fluorescence intensity 
Page 19 of 25
John Wiley & Sons
Arthritis & Rheumatology
20 
 
Table III- Frequency of intracellular expression of cytokines and their respective MFI in 
CD8
+
T cells from PB and SF from RA patients. 
 
SF PB Wilcoxon
 
 
Mean (n=10) Mean (n=10) p 
Intracellular cytokines (% from total CD8
+
T cells) 
IL-6 5.1 ± 1.3 2.0 ± 0.4 0.047 
TNF-α 8.7 ± 3.7 2.5 ± 0.7 0.008
 
IFN-γ 6.9 ± 2.2 4.5 ± 1.9 NS
a
 
IL-17A 11.7 ± 6.0  7.5 ± 2.2 NS 
IL-10 8.5 ± 6.7 2.0 ± 1.2 NS 
GrzB
b
 23.6 ± 5.6 35.9 ± 9.3 NS 
Perforin 4.3 ± 1.3 10.8 ± 6.9 NS 
MFI
c
 (within the cytokine-positive CD8
+
T cells) 
IL-6 24.3 ± 7.8 34.1 ± 14.4 NS 
TNF-α 23.3 ± 5.0 29.0 ± 10.8 NS 
IFN-γ 28.2 ± 5.5 36.7 ± 11.9 NS 
IL-17A 34.9 ± 9.0 45.1 ± 12.8 NS 
IL-10 72.9 ± 56.1 39.9 ± 22.0 NS 
GrzB 121.6 ± 90.1 127.7 ± 44.3 NS 
Perforin 20.7 ± 4.8 39.0 ± 19.1 NS 
a) NS: non-significant: b) GrzB: Granzyme B, c) MFI: mean fluorescence intensity 
 
Page 20 of 25
John Wiley & Sons
Arthritis & Rheumatology
23 
 
Figure Legends 
Figure 1 – Functional phenotyping of peripheral blood CD8
+
T cells shows altered 
frequencies of subsets expressing activation, homing, memory and effector molecules in 
active and remission RA patients when compared to controls. A: Boxplots representing the 
90%, 75%, median, 25% and 10% ranges of the frequency of total circulating CD8
+
T cells 
within the lymphocyte gate. B: Representative dot-plots of CD62L vs CD27 gated on CD8
+
 T 
cells for each group. Boxplots representing the 90%, 75%, median, 25% and 10% ranges of 
the frequency of circulating CD8
+
T cell subsets within the total CD8
+
T cell pool: 
CD27
+
CD62L
+
CCR7
+
,  CD27
-
CD62L
-
, C: Boxplots representing the 90%, 75%, median, 25% and 
10% ranges of the frequency of circulating activated CD8
+
T cell subsets within the total 
CD8+T cell pool: CD25
+
,  CD69
+
,  CD69
+
CD62L
-
, D: Boxplots representing the 90%, 75%, 
median, 25% and 10% ranges of the frequency of circulating CD8
+
T cell subsets expressing 
homing molecules within the total CD8
+
T cell pool CXCR4
+
,  CXCR4
+
CD69
+
CD62L
-
. P values 
calculated by one-way ANOVA followed by LSD post-hoc test. Control: N = 64; Active RA: N = 
34; Remission RA: N = 44. 
Figure 2 – Functional phenotyping of CD8
+
T cells from paired peripheral blood and synovial 
fluid from RA patients shows increased frequencies of CD8
+
T cells expressing effector, 
activation and homing molecules in the synovial fluid. Boxplots representing the 90%, 75%, 
median, 25% and 10% ranges of the frequency of circulating CD8
+
T cell subsets within the 
total CD8
+
T cell pool: A: CD27
+
CD62L
-
 and CD27
-
CD62L
-
CCR7
-
, B. CD25
+
, CD69
+
 and 
CD69
+
CD62L
-
, C. CXCR4
+
, CXCR4
+
CD62L
-
 and CXCR4
+
CD69
+
. P values calculated by Wilcoxon 
non parametric test. Synovial fluid (SF) and peripheral blood (PB): N = 10. 
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Figure 3 – Values observed in the patients’ PB mirror those in the SF, and the percentage of 
CD8
+
T cells with an inflammatory phenotype increase with the patients’ DAS28 A: 
Correlation plots between CD8
+
T cell subsets in the PB and SF of RA patients (N = 10). B: 
Correlation plots between cytokine production by total CD8
+
T cells in the PB and SF of RA 
patients (N = 10). C:  Correlation plots between PB CD8
+
T cell subsets and DAS28 of RA 
patients (N = 96). D: Correlation plots between PB cytokine production by total CD8
+
T cells 
and DAS28 of RA patients (N = 96). Correlations considered weak for r>0.2, moderate for 
r>0.3, strong for r >0.5 and very strong for r >0.75. Significance achieved for p < 0.05. A-G: 
Values obtained using the Spearman correlation. H-L: Values obtained using the Pearson 
correlation. 
Supplemental Figure: The loss of circulating total CD8
+
T cells, as well as activated (CD69
+
) 
and effector (CD62L
-
) CD8
+
T cell subsets expressing the CXCR4 homing molecule in RA 
patients with active disease when comparing to healthy controls, seems to derive from their 
accumulation in the inflamed joints. The graph shows the mean frequency ±StdEr for each 
subset for healthy controls (HC, n=64) and paired peripheral blood (PB) and synovial fluid 
(SF) from patients with active RA (n=10). 
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